Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)

SHA:603229 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,129	1,096	1,124	608.85	564.55	739.11
Trading Asset Securities	6.3	2.24	-	4.02	110	-
Cash & Short-Term Investments	1,135	1,099	1,124	612.87	674.55	739.11
Cash Growth	10.73%	-2.29%	83.44%	-9.14%	-8.73%	116.06%
Accounts Receivable	209.8	196.58	132.75	134.81	66.24	45.56
Other Receivables	2.91	1.63	2.82	8.49	1.49	0.84
Receivables	212.72	198.21	135.57	143.3	67.73	46.4
Inventory	424.36	400.95	365.18	320.57	243.44	190.17
Other Current Assets	21.2	11.48	49.75	59.97	34.86	4.25
Total Current Assets	1,794	1,709	1,675	1,137	1,021	979.93
Property, Plant & Equipment	1,036	1,041	1,046	950.94	601.46	299.92
Long-Term Investments	72.56	72.56	67.37	50.14	32.64	13.08
Other Intangible Assets	152.28	155.39	150.37	161.98	164.2	77.3
Long-Term Deferred Tax Assets	1.26	0.46	-	6.87	4.47	4.72
Other Long-Term Assets	4.25	3.99	12.71	8.69	16.1	6.74
Total Assets	3,060	2,982	2,952	2,315	1,839	1,382
Accounts Payable	264.59	351.64	410.85	519.32	402.25	171.26
Accrued Expenses	26.89	46.87	40.11	42.91	31.63	22.35
Short-Term Debt	330.97	270.31	300.26	160.12	65.07	41.04
Current Portion of Long-Term Debt	-	-	-	9.16	-	-
Current Portion of Leases	1.04	1.04	0.87	-	-	-
Current Income Taxes Payable	5.36	2.53	10.21	-	5.81	1.74
Current Unearned Revenue	1.19	0.91	7.06	12.63	23.23	2.53
Other Current Liabilities	1.59	1.23	1.61	1.28	2.33	4.95
Total Current Liabilities	631.62	674.53	770.97	745.42	530.32	243.87
Long-Term Debt	44.23	-	-	72.74	44.86	-
Long-Term Leases	0.4	1.08	2.04	-	-	-
Long-Term Unearned Revenue	36.8	34.89	34.91	23.51	9.46	10.94
Long-Term Deferred Tax Liabilities	-	-	2.07	12.51	-	-
Total Liabilities	713.05	710.5	809.99	854.19	584.64	254.81
Common Stock	830.3	830.3	593.07	401.87	287.05	239.21
Additional Paid-In Capital	440.23	440.23	677.45	394.72	509.54	557.38
Retained Earnings	1,128	1,002	871.92	665.46	459.36	331.37
Comprehensive Income & Other	-0.81	-0.83	-0.86	-0.91	-1.14	-1.08
Shareholders' Equity	2,347	2,272	2,142	1,461	1,255	1,127
Total Liabilities & Equity	3,060	2,982	2,952	2,315	1,839	1,382
Total Debt	376.63	272.43	303.17	242.02	109.93	41.04
Net Cash (Debt)	758.8	826.1	821.06	370.85	564.62	698.06
Net Cash Growth	5.05%	0.61%	121.40%	-34.32%	-19.12%	134.94%
Net Cash Per Share	0.91	1.00	1.00	0.46	0.71	0.94
Filing Date Shares Outstanding	790.92	828.3	830.3	787.66	787.66	787.66
Total Common Shares Outstanding	790.92	830.3	830.3	787.66	787.66	787.66
Working Capital	1,162	1,035	903.76	391.28	490.26	736.06
Book Value Per Share	2.97	2.74	2.58	1.86	1.59	1.43
Tangible Book Value	2,195	2,116	1,991	1,299	1,091	1,050
Tangible Book Value Per Share	2.78	2.55	2.40	1.65	1.38	1.33
Buildings	-	261.11	224.84	168.11	150.71	135.9
Machinery	-	559.12	510.1	278.07	223.16	211.87
Construction In Progress	-	495.66	526.23	685.01	379.24	77.04

Source: S&P Global Market Intelligence. Standard template. Financial Sources.